How to Reconstitute Retatrutide: BAC Water Volumes, Unit Conversions and a Worked Example

Retatrutide (Eli Lilly code LY3437943) is a triple agonist that engages the GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data in obesity and type 2 diabetes populations have been published in the New England Journal of Medicine and The Lancet, and a Phase 2a substudy in metabolic dysfunction-associated steatotic liver disease (MASLD) appeared in Nature Medicine in 2024. As a research compound, retatrutide is commonly handled as a lyophilized (freeze-dried) powder that a researcher brings into solution with a diluent before pipetting or further laboratory use.

This guide walks through that reconstitution step. It covers what bacteriostatic water is and its preservative role, how to calculate the resulting concentration for example vial sizes, how insulin-syringe unit markings map to milliliters, a fully worked mg-to-mcg/ml example, and how to store a reconstituted vial afterward. Every number below is an arithmetic exercise for research-scale handling of a research compound. None of it describes, recommends, or implies a route, frequency, or amount for administration to a human being.

How reconstitution volume determines concentration

A vial of lyophilized peptide contains a fixed mass of peptide. That mass does not change when you add diluent. What changes is how that fixed mass is distributed through a liquid volume, which is exactly what "concentration" means.

The relationship is simple division:

Concentration (mcg/ml) = total peptide mass (mcg) / diluent volume added (ml)

Add less water, get a higher concentration. Add more water, get a lower concentration. Because 1 mg equals 1000 mcg, a 10 mg vial contains 10,000 mcg of peptide regardless of whether you plan to add 1 ml or 10 ml of bacteriostatic water. Only the diluent volume decides how concentrated the resulting solution is.

This matters because the single most common practical error in peptide handling is not a chemistry mistake, it is a units mistake: confusing peptide mass (mg, a fixed property of the vial) with solution volume (ml, a variable you choose). Get the two confused and every subsequent pipetting step compounds the error.

Choosing a diluent: bacteriostatic water vs. sterile water

Two diluents are relevant for reconstituting a lyophilized peptide vial in a research setting.

Bacteriostatic water (BAC water) is sterile water with benzyl alcohol added as a preservative. The benzyl alcohol does not sterilize the solution outright, but it supports repeated draws from the same vial, which is useful for a research protocol involving a dilution series or repeated pipetting sessions.

Sterile water contains no preservative. Whether a preservative-free diluent is needed, and how a sterile-water solution should be handled after opening, depends on the specific research protocol.

No retatrutide-specific reconstitution study has been published in the trial literature, so no published trial data confirm a required diluent pH or an incompatibility with bacteriostatic water for this compound specifically. If you want a fuller comparison across diluent types, see our guide on bacteriostatic, acetic acid, and sterile water.

Acetic Acid Wateraccessories

Dilute 0.6% acetic-acid diluent at around pH 3.8, for reconstituting research peptides that stay cloudy in plain bacteriostatic water, such as IGF-1 LR3 and Cagrilintide. Two-step protocol. Each vial is sealed and ready to use.

Reconstitution procedure

BAC water volumes and the resulting concentration

The table below shows how the same vial produces different concentrations depending on how much bacteriostatic water is added. These are illustrative combinations for demonstrating the arithmetic, not a recommendation to prepare any specific one.

The pattern is the same division shown earlier: mass in mcg divided by volume in ml. Larger diluent volumes produce lower, more dilute concentrations; smaller diluent volumes produce higher, more concentrated solutions.

Worked example: from a 10 mg vial to a draw volume

Here is the full arithmetic chain, using round numbers purely to illustrate the calculation method, not as a suggested amount for any use.

Step 1: Convert mass to micrograms. A 10 mg vial contains 10 mg times 1000 mcg/mg = 10,000 mcg of peptide.

Step 2: Choose a diluent volume and calculate concentration. Adding 2 ml of bacteriostatic water gives a concentration of 10,000 mcg / 2 ml = 5000 mcg/ml.

Step 3: Calculate the draw volume for an arbitrary target mass. The general formula is draw volume (ml) = desired mass (mcg) / concentration (mcg/ml). If a protocol calls for withdrawing, say, 500 mcg from this solution: 500 mcg / 5000 mcg/ml = 0.1 ml.

Step 4: Convert that draw volume to syringe units. On a standard U-100 insulin syringe, 1 ml corresponds to 100 units, so 1 unit = 0.01 ml. A draw of 0.1 ml therefore corresponds to 10 units on a U-100 syringe.

Every number in this chain traces back to two inputs you control directly: the diluent volume you add, and the target mass you want to isolate in a given draw. Nothing here specifies a route or a schedule; it is unit conversion applied to a research vial.

Retatrutidemetabolic

First-ever triple-action weight management peptide targeting three receptors at once: GLP-1, GIP, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.

Bacteriostatic Wateraccessories

USP-grade sterile water with 0.9% benzyl alcohol (near-neutral, ~pH 6) - the standard solvent for reconstituting lyophilized peptides. Essential accessory for any peptide research. Each vial is sealed and ready to use.

Graduated Measuring Syringe 1 mL 31G x 6 mmaccessories

Sterile 1 mL graduated laboratory syringe with a 31G x 6 mm fine tip. Individually wrapped, latex-free, pyrogen-free, PVC-free, with a high-contrast 0.01 mL black scale for precise liquid measuring and transfer.

Alcohol Prep Pads 30 x 65 mmaccessories

Sterile, individually sealed alcohol pads with 70% isopropyl. 30 x 65 mm folded surface for vial-top, hard-surface, and skin disinfection in research workflows.

Lab Measuring Syringe + Prep Wipes Set (1 mL 31G)accessories

Bundle of 1 mL 31G x 6 mm graduated lab measuring syringes and 70% IPA alcohol prep wipes in matched counts. One wipe per syringe, lower per-unit cost than buying separately.

Storage after reconstitution

No published retatrutide trial data address chemical stability, sterility duration, or degradation kinetics of a researcher-reconstituted solution, for the same reason noted above: Lilly's clinical supply chain never reconstituted lyophilized powder in the field. What follows is general research-peptide handling convention, not a retatrutide-specific finding.

Bacteriostatic water's benzyl alcohol preservative supports repeated draws from the same vial over a multi-week window, commonly cited as up to 28 days when kept refrigerated (2 to 8 degrees Celsius); this is a general handling convention across the peptide-research field, not a published retatrutide-specific shelf-life result. Sterile water contains no such preservative, so it does not support the same repeated-draw storage window.

Reconstituted peptide solutions are generally more prone to hydrolysis, oxidation, and aggregation than the original lyophilized powder, so unopened lyophilized vials remain the more stable long-term storage form whenever a research timeline allows delaying reconstitution. Once a vial is reconstituted, avoid repeated freeze-thaw cycles: freeze-thaw cycling itself, through ice-crystal formation, is a documented mechanism of protein and peptide structural damage independent of the specific compound involved.

What the clinical literature actually shows (and does not show)

It is worth being precise about what the published retatrutide dataset does and does not tell a researcher.

Retatrutide's mechanism, described by Coskun et al. in Cell Metabolism (2022, PMID 35985340), is a single 39-amino-acid peptide built on a GIP-hormone backbone with a C20 fatty diacid attached via an AEEA-gamma-Glu linker at the Lys4 position for albumin binding. On human receptors it is reported as roughly 0.3x as potent as native glucagon at the glucagon receptor, 0.4x as potent as native GLP-1 at the GLP-1 receptor, and about 8.9x more potent than native GIP at the GIP receptor, a GIP-receptor-biased profile that mechanistically distinguishes it from single or dual incretin agonists. That fatty-acid modification is the structural basis for an elimination half-life of roughly 6 days, as measured in the Phase 1b multiple-ascending-dose trial (Urva et al., Lancet 2022, PMID 36354040), the pharmacological basis for the once-weekly dosing schedule used in trials.

The Phase 2 obesity trial (Jastreboff et al., NEJM 2023, PMID 37366315) randomized adults with obesity or overweight to placebo or once-weekly retatrutide at 1, 4, 8, or 12 mg for 48 weeks, reporting mean body-weight change at 48 weeks of minus 8.7% (1 mg), minus 17.1% (4 mg pooled), minus 22.8% (8 mg pooled), and minus 24.2% (12 mg), against minus 2.1% for placebo. A separate Phase 2 trial in type 2 diabetes (Rosenstock et al., Lancet 2023, PMID 37385280) found roughly 16.9% mean weight reduction at the 12 mg dose alongside clinically meaningful HbA1c improvements. A Phase 2a substudy in metabolic dysfunction-associated steatotic liver disease (Sanyal et al., Nature Medicine 2024, PMID 38858523) reported dose-dependent relative liver-fat reductions from 42.9% at 1 mg up to 82.4% at 12 mg over 24 weeks, with liver-fat normalization achieved in 79 to 86% of participants at the higher doses.

Gastrointestinal adverse events, nausea, vomiting, diarrhea, and constipation, were consistently the most common adverse events across the Phase 1b, Phase 2 obesity, and Phase 2 diabetes trials, generally mild to moderate and concentrated during dose-escalation, consistent with the broader GLP-1/GIP receptor-agonist drug class (Urva et al., Lancet 2022, PMID 36354040; Jastreboff et al. 2023, PMID 37366315). None of this safety data originates from, or applies to, laboratory handling of the lyophilized research compound; it describes outcomes in supervised human clinical trials, not bench-scale research use.

As of July 2026, retatrutide is not approved by the FDA, EMA, or any other regulator. Lilly's Phase 3 program is ongoing; industry commentary about possible future filing or approval timelines is market speculation, not a regulatory fact, and is not repeated here as if it were one.

Metabolic Researchmetabolic

GIP/GLP-1/Glucagon agonists and metabolic pathways

Frequently asked questions

This article describes laboratory arithmetic and handling technique for a research compound. It is not medical advice, not a dosing instruction, and not a recommendation for human or veterinary use. Retatrutide is sold exclusively for in-vitro and laboratory research.